Compare Merck & Co., Inc. (MRK) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Raytheon Technologies Corp — how do they compare? Merck & Co., Inc. trades at $141.98 (market cap $351.28B), while Raytheon Technologies Corp trades at $184.66 (market cap $248.42B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Raytheon Technologies Corp for 78 Days on average.
| MRK | RTX | |
|---|---|---|
Market Cap | $351.28B | $248.42B |
Volume | 7,969,665 | 4,380,368 |
Sector | Health | Industrials |
52-Week High | $156.43 | $225.49 |
52-Week Low | $82.49 | $157.00 |
Typical Hold Time | 98 Days | 78 Days |
Enterprise Value | $398.04B | $278.97B |
Dividend Yield | 2.39% | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
RTX trades at $184.32, up 0.56% today, with strong fundamental momentum as revenue grew to $88.6B in 2025 and net income reached $6.73B. The company has beaten earnings estimates for three consecutive quarters, supported by a massive $289B backlog. Technical indicators show a bearish short-term trend despite bullish oscillators, while analyst consensus remains strongly positive with a $237.60 price target.
RTX presents a compelling investment case with robust defense sector tailwinds and consistent earnings outperformance. Key risks include execution challenges in managing the large backlog and potential defense budget volatility. The stock offers 29% upside to consensus targets, making it attractive for long-term investors despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
